MX2008002512A - Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada. - Google Patents

Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.

Info

Publication number
MX2008002512A
MX2008002512A MX2008002512A MX2008002512A MX2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A
Authority
MX
Mexico
Prior art keywords
controlled release
compositions containing
drug compositions
containing controlled
matrices
Prior art date
Application number
MX2008002512A
Other languages
English (en)
Inventor
Ali Rajabi-Siahboomi
Kurt Alan Fegely
Kara Young
Pankaj Rege
Original Assignee
Bpsi Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bpsi Holdings Inc filed Critical Bpsi Holdings Inc
Publication of MX2008002512A publication Critical patent/MX2008002512A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion esta dirigida a una formulacion con liberacion controlada para una forma de dosis oral que es formulada en una matriz hidrofilica expandible. La formulacion con liberacion controlada contiene una mezcla la hipromelosa y ftalato acetato de polivinilo y permite combinar ingredientes activos farmaceuticos entre si para ser liberados de una manera controlada.
MX2008002512A 2005-08-26 2006-08-25 Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada. MX2008002512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71172405P 2005-08-26 2005-08-26
PCT/US2006/033309 WO2007025182A2 (en) 2005-08-26 2006-08-25 Drug compositions containing controlled release hypromellose matrices

Publications (1)

Publication Number Publication Date
MX2008002512A true MX2008002512A (es) 2008-04-03

Family

ID=37772457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002512A MX2008002512A (es) 2005-08-26 2006-08-25 Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.

Country Status (13)

Country Link
US (1) US20070048377A1 (es)
EP (1) EP1926479A4 (es)
JP (1) JP2009506070A (es)
KR (1) KR20080047571A (es)
CN (1) CN101247790A (es)
AU (1) AU2006282900B2 (es)
BR (1) BRPI0615135A2 (es)
CA (1) CA2620108A1 (es)
IL (1) IL189631A0 (es)
MX (1) MX2008002512A (es)
RU (1) RU2414241C2 (es)
WO (1) WO2007025182A2 (es)
ZA (1) ZA200801478B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068076A2 (en) * 2010-11-15 2012-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations containing soluble drugs
NL2009273A (en) 2011-08-31 2013-03-04 Asml Netherlands Bv Level sensor arrangement for lithographic apparatus, lithographic apparatus and device manufacturing method.
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
RU2624857C1 (ru) * 2016-01-26 2017-07-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Фармацевтическая композиция с противогрибковой активностью и способ ее получения
WO2019098300A1 (ja) 2017-11-16 2019-05-23 日本新薬株式会社 放出制御製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114472T1 (de) * 1989-09-21 1994-12-15 American Cyanamid Co System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe.
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6726931B2 (en) * 2002-04-08 2004-04-27 Standard Chem. & Pharm. Co., Ltd. Process for preparing oral sustained-release formulation of felodipine
JP2006507298A (ja) * 2002-10-30 2006-03-02 ファルマシア コーポレーション 経口持続放出型錠剤、ならびにその製造法および使用法
ES2545454T3 (es) * 2002-12-10 2015-09-11 Nortec Development Associates, Inc. Método de preparación de formulaciones biológicamente activas
EP1656126B1 (en) * 2003-08-12 2011-08-10 Kyungdong Pharm. Co., Ltd. Preparing method for controlled released type tablet comprising tamsulosin hcl and the tablet produced thereof
WO2005034954A2 (en) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
SG147450A1 (en) * 2003-10-29 2008-11-28 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof

Also Published As

Publication number Publication date
EP1926479A2 (en) 2008-06-04
WO2007025182A2 (en) 2007-03-01
ZA200801478B (en) 2008-12-31
BRPI0615135A2 (pt) 2016-09-13
RU2414241C2 (ru) 2011-03-20
KR20080047571A (ko) 2008-05-29
EP1926479A4 (en) 2013-01-09
RU2008111497A (ru) 2009-10-10
JP2009506070A (ja) 2009-02-12
CA2620108A1 (en) 2007-03-01
IL189631A0 (en) 2008-06-05
AU2006282900A1 (en) 2007-03-01
US20070048377A1 (en) 2007-03-01
WO2007025182A3 (en) 2007-09-07
CN101247790A (zh) 2008-08-20
AU2006282900B2 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
MX2008002512A (es) Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
HK1126394A1 (en) Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
AP1954A (en) Controlled release compositions comprising nimesulide.
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
SI2529622T1 (en) Bruton tyrosine kinase inhibitors
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
WO2009063222A3 (en) Solid compositions
TW200624126A (en) New modified release tablet formulations for proton pump inhibitors
NZ600640A (en) Abuse-resistant formulations
AR061771A1 (es) Sistema de administracion terapeutica
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
UA116334C2 (uk) Тверді форми дозування бендамустину
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
TW200635617A (en) Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
UA106361C2 (ru) Фармацевтическая композиция для лечения эссенциальной тромбоцитемии
CL2008000931A1 (es) Particula solidad de vacuna oral entrecruzada que contiene un ingrediente farmaceuticamente activo un bioadhesivo, un oligasacarido, una mezcla mediadiora que comprende un emulsionante y uno o mas monosacaridos y/o disacaridos; metodo para su preparacion; uso de la particula solidad de vacuna oral.
WO2010019279A8 (en) Pharmaceutical compositions configured to deter dosage form splitting

Legal Events

Date Code Title Description
FA Abandonment or withdrawal